Gilead Sciences Inc (USD)
GILD
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
IndustryDrug Manufacturers - Major
Day Range65.00 | 65.75
52-Wk Range60.32 | 76.44
Last Close65.30
Mkt Cap (m)82,699.54
Dividend yield3.77%
ISINUS3755581036
Volume2,297,616
Exchange VenueNAS

Company Profile

Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases.

Key Information
Price/Earning14.10
Price/Book3.66
Price/Sales3.77
P/CF10.25
Rev Growth (3 year avg)-12.15
EPS Growth (3 year avg)-0.30
Operating Margin % 37.06
Net Margin %24.65
Return on Equity26.08
Debt/Equity1.28

Legal Documents

Prospectus
en 18/09/2017
Annual Report
en 31/12/2018

Financials

Income Statement
USD201320142015201620172018
Revenue (m)11,20224,89032,63930,39026,10722,127
Operating Income (m)4,52415,26522,19317,63314,1248,200
Net Income (m)3,07512,10118,10813,5014,6285,455
Basic EPS2.017.9512.3710.083.544.20
Avg. Diluted Shares Outstanding (m)1,6951,6471,5211,3581,3191,308
Balance Sheet
USD201320142015201620172018
Current Assets (m)7,27417,71424,76320,44531,82335,836
Non Current Assets (m)15,22316,95027,07636,53238,46027,839
Total Assets (m)22,49734,66451,83956,97770,28363,675
Current Liabilities (m)6,3895,7769,8939,21911,63510,605
Total Liabilities (m)------
Total Equity (m)11,36915,42618,53418,88720,44221,387
Cash Flows
USD201320142015201620172018
Operating Cash Flows (m)3,10512,81820,32916,66911,8988,400
Capital Expenditure (m)-191-557-747-748-590-924
Figures are quoted in USD unless stated otherwise
0.33 (0.51%)
$
65.63
Last Price